Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2 -receptor antagonist: the DILIPO study

2011 ◽  
Vol 13 (3) ◽  
pp. 327-336 ◽  
Author(s):  
Doron Aronson ◽  
Joseph G. Verbalis ◽  
Matthias Mueller ◽  
Henry Krum ◽  
Keyword(s):  
Receptor Antagonist ◽  
Arginine Vasopressin ◽  
Term Treatment ◽  
Long Term Treatment ◽  
V2 Receptor ◽  
Vasopressin V2 Receptor Antagonist ◽  
Short And Long Term ◽  
Dilutional Hyponatraemia ◽  
V2 Receptor Antagonist

Aquaretic and hormonal effects of a vasopressin V2 receptor antagonist after acute and long-term treatment in rats

2000 ◽  
Vol 394 (1) ◽  
pp. 131-138 ◽  
Author(s):  
Colette Lacour ◽  
Gérard Galindo ◽  
Françoise Canals ◽  
Danielle Segondy ◽  
Catherine Cazaubon ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Term Treatment ◽  
Hormonal Effects ◽  
Vasopressin V2 Receptor ◽  
Long Term Treatment ◽  
V2 Receptor ◽  
Vasopressin V2 Receptor Antagonist ◽  
V2 Receptor Antagonist

scholarly journals Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Simone Janett ◽  
Pietro Camozzi ◽  
Gabriëlla G. A. M. Peeters ◽  
Sebastiano A. G. Lava ◽  
Giacomo D. Simonetti ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Treatment ◽  
Cross Sectional ◽  
Magnesium Metabolism ◽  
Poor Renal Function ◽  
Long Term Treatment

In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with another but not with a histamine type-2 receptor antagonist. The association between proton-pump inhibitors and magnesium metabolism was addressed in 14 case-control, cross-sectional studies. An association was found in 11 of them: 6 reports found that the use of proton-pump inhibitors is associated per se with a tendency towards hypomagnesemia, 2 found that this tendency is more pronounced in patients concurrently treated with diuretics, carboplatin, or cisplatin, and 2 found a relevant tendency to hypomagnesemia in patients with poor renal function. Finally, findings likely reflecting decreased intestinal magnesium uptake were observed on treatment with proton-pump inhibitors. Three studies did not disclose any relationship between magnesium metabolism and treatment with histamine type-2 receptor antagonists. In conclusion, proton-pump inhibitors may cause hypomagnesemia. In these cases, switching to a histamine type-2 receptor antagonist is advised.

Long-term treatment with angiotensin II type 1 receptor antagonist, CV-11974, restores β-catenin mRNA expression in volume-overloaded rabbit hearts

2002 ◽  
Vol 17 (1) ◽  
pp. 36-41 ◽  
Author(s):  
Makoto Itoh ◽  
Y. Takeishi ◽  
Shigekazu Nakada ◽  
Takuya Miyamoto ◽  
Yuichi Tsunoda ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Receptor Antagonist ◽  
Mrna Expression ◽  
Term Treatment ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document